Mango Sciences, Inc., a leading data science company focused on emerging markets, today announced the completion of an investment into the company by Spartech Ventures, a Dubai-based venture capital firm, as part of their current funding round.
Mango Sciences is tackling the fundamental issue of access to precision medicine for populations overlooked in the emerging markets. Partnering with leading hospitals and clinics in Asia and the Middle East, the company’s platform unlocks key health insights from complex clinical data, usually siloed in hospital systems and underutilised to better understand the cost of care, improve operational efficiencies and enable personalised care for all populations.
Mango’s AI platform ensures hospital managers and clinicians are able to make decisions on care delivery and appropriate treatments in a timely fashion. Having recently launched in the GCC, they are engaged with some of the largest hospital chains in the region to help them better use data with AI across their organisations.
“Mango has been positioned very nicely to play a key role in the advancement of healthcare worldwide, especially in emerging markets. That fact combined with stellar business performance makes it a unique investment we are excited about. It combines impact with an exciting upside prospect from an investment standpoint”, said Yagub Alserkal, Managing Director of Spartech Ventures. “We are excited about how Mango’s data platform can transform care delivery for people in the GCC, catalysing clinical research and access to truly personalised care for everyone”, added Amer Fatayer, Managing Director of Spartech Ventures.
Dr Mohit Misra, Chief Executive Officer and Co-Founder of Mango Sciences said, “Mango’s unique ability to collaborate across the healthcare ecosystem allows us to leverage data to identify unmet need and help finance innovative immunotherapies for patients where affordability is a key issue to access.”